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Opinion statement
• In acute spinal cord ischemia syndrome (ASCIS), treatment recommendations are
derived from data of cerebral ischemic stroke, atherosclerotic vascular disease and
acute spinal cord injury. Besides acute management, secondary prevention is of
major importance. Pathologies affecting the aorta as well as underlying cerebro-
vascular conditions should be treated whenever possible.
• ASCIS may occur after aortic surgery, less often after thoracic endovascular aor-
tic repair (TEVAR). Protocols are proposed.
• Acute spinal cord hemorrhage can be treated surgically and/or pharmacologically.
• Symptomatic treatment in patients with a spinal cord lesion is of major importance.
Depending on level and extension of the lesion, there is a risk for systemic and neurological
complications, which may be life-threatening.
• Each spinal vascular malformation is a unique lesion that needs an individualized treat-
ment algorithm. In case of a symptomatic vascular malformation, endovascular interven-
tion is the primary treatment option.
• Spinal dural Arteriovenous fistula (AVF) may be treated endovascularly or surgically. If
preoperative localization of the fistula is possible, surgery is feasible with a low complica-
tion rate. In comparison, endovascular approaches are less invasive.
• Spinal AVM are rather treated endovascularly than surgically or in a stepwise multidisci-
plinary approach.
• Symptomatic and exophytic spinal cavernous angiomas should be treated surgically.
Deep spinal cavernous angiomas that are asymptomatic or only show mild symptoms
can be observed.
Introduction
The 3 major groups of vascular diseases of the spinal
cord are acute spinal cord ischemia syndrome
(ASCIS), spinal cord hemorrhage, and spinal vascu-
lar malformations.
Acute spinal cord ischemia syndrome (ASCIS)
(Fig. 1c–f)
Compared with acute cerebrovascular diseases
ASCIS is a rare condition, accounting for 5 % to
8 % of all acute myelopathies and 1 % to 2 %
of all vascular neurological pathologies [1, 2]. It
is mostly a single event. Main causes of ASCIS
are interventions and pathologies affecting the aor-
ta [3, 4•, 5]. Further etiologies include any pathol-
ogy that may also cause acute cerebral ischemia,
(eg, atherosclerosis, cardiac, and arterio-arterial em-
bolism, infection, hypercoagulable state, and vascu-
litis). Severe hypotension, cardiac arrest, or rarely,
spinal venous pathologies may also lead to ASCIS
[1–3]. The clinical spectrum is broad, ranging from
complete or incomplete myelopathy, para- or
quadriparesis, loss of sensation, especially of pain
and temperature, and loss of bladder function.
Many patients suffer associated back pain [2]. In
contrast to cerebral ischemia, preceding transient
ischemic attacks affecting the spinal cord are rare.
Symptoms often develop slower than in acute ce-
rebral ischemia, sometimes taking up to several
hours [6]. The functional long-term outcome after
ASCIS depends mainly on the severity of initial
neurological deficits, especially of motor deficits.
Poor prognostic factors are female sex, higher
age, lack of improvement within the first 24 hours,
and affection of the cone. The frequency of recov-
ery to independent gait varies from 11 % to
46 %, 20 % to 57 % of the patients remain
wheelchair bound. Case fatality rates range from
9 % to 20 % [1–3, 7–9]. Treatment recommenda-
tions concerning acute stage and secondary pre-
vention are derived from cerebral ischemia,
atherosclerotic vascular disease, and acute spinal
cord injury. Besides acute management, early sec-
ondary prevention is important. An underlying pa-
thology should be treated whenever possible [6,
10••, 11••] (Class I).
Spinal cord hemorrhage (Fig. 1i–j)
Hemorrhage affecting the spinal cord is rare, and is
more frequent in men than in women. It may be
caused by trauma, anticoagulation, hereditary or ac-
quired bleeding disorders, or bleeding from spinal
vascular malformations, spinal artery aneurysms,
primary spinal cord tumors (eg, hemangioblasto-
mas or spinal cord metastases). Rarely it is sponta-
neous and in many cases the etiology remains
undiscovered. The hemorrhage can be intramedul-
lary, subarachnoidal, subdural, or epidural [12].
Hematomyelia is caused by bleeding within the spi-
nal cord. The blood tends to dissect longitudinally
above and below the hemorrhage, disrupting gray
matter more than white matter [13]. Spinal sub-
arachnoidal hemorrhage accounts for less than
1 % of all subarachnoidal hemorrhages. Spinal epi-
dural hemorrhage occurs at least 4 times more
commonly than spinal subdural hemorrhage.
Patients with spinal cord hemorrhage usually pres-
ent with acute symptoms with back or neck pain
that may be intense, knife-like, and often show
a radicular component. Patients with spinal sub-
arachnoidal hemorrhage may additionally show
symptoms resembling meningitis, such as menin-
geal irritation with headache, neck stiffness, distur-
bance of consciousness and epileptic seizures and
are also often misdiagnosed as having cerebral
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Figure 1. a b A 50-year-old man with recurrent extensive spinal intradural arteriovenous malformation. a Catheter angiography
showing the artery of Adamkiewicz originating from the left intercostal artery at the Th10 level (black arrowheads). The an-
terior spinal artery is rather tortuous. The vessel convolute (nidus) is seen at the level L2-3 (black arrow). b High resolution
sagittal heavy T2-weighted (CISS) MRI reveals extensive worm-like intraspinal vessels in the thoracolumbar region. Notice the
myelopathy signal (white arrow). c–f A 72-year-old man with cramp-like pains in the thighs and the calves. MRI showing
evidence of spinal cord ischemia. c Notice the T2 bright signal within the spinal cord from the Th11 level down to the conus
medullaris. d Sagittal diffusion-weighted image showing abnormal signal in the affected part of the spinal cord. Axial T2-
weighted images show the possible signal abnormality pattern. e Snake-eyes (or snake-bite) pattern at Th12. f H-like pattern
at L1. g–h Intramedullary cavernous angioma at the Th7 level. Sagittal g and axial hT2-weighted images. Notice the bright
internal signal surrounded by the dark hemosiderin ring. i–j Intraspinal perimedullary extensive hemorrhage, often difficult to
detect. Sagittal T2- i and T1-weighted j images showing low and bright signal of the hemorrhage (arrows).
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hemorrhage [12]. Specific treatment of acute spi-
nal cord hemorrhage is surgical and/or pharmaco-
logical [12, 13].
Spinal vascular malformations
Most frequent spinal vascular malformations, caus-
ing hemodynamic changes of the spinal cord, are
classified into different types, depending on their
location and vascular pathology: spinal dural arte-
riovenous fistulas (AVF), arteriovenous malforma-
tions (AVM), and cavernous angiomas. Dural
arteriovenous fistula (AVF) is the most common
type of spinal vascular malformations. Spinal dural
AVF are more common in men, usually presenting after
the forth decade and are probably acquired. The etiology
of spinal dural AVF is unknown. The clinical presenta-
tion is mostly a slowly progressive, often step-wise and
rarely acute myeloradiculopathy. A venous congestion
caused by arterial overload of venous drainage due to
the fistula, initiates edema and mylopathy of the spinal
cord leading to a broad range of clinical symptoms.
Spinal cord hemorrhage is almost never seen in
patients with spinal dural AVF. Occlusion of the fis-
tula by surgery or endovascular embolization is in-
dicated and can improve or at least stabilize the
clinical condition [2, 14–18]. Early recognition of
spinal dural AVF with subsequent aggressive treat-
ment may best prevent further neurologic decline.
Having this mostly vascular entity in mind and ini-
tiating spinal imaging early, may significantly im-
pact patient’s outcome [19].
The second most common vascular malformation
of the spinal cord is the spinal arteriovenous malfor-
mation (AVM) (Fig. 1a–b). Clinical symptoms are usu-
ally first seen in adolescence or early adulthood.
Damage of the spinal cord is most often caused by
acute intramedullary or subarachnoidal hemorrhage,
venous congestion, and less frequently by mass or
steal effect. Spinal AVM are rather treated endovascu-
larly than surgically or in a stepwise multidisciplinary
approach [2, 15, 18, 20].
The third most common vascular malformation
of the spinal cord is the spinal cavernous angioma
(Fig. 1g–h). It can cause a transverse spinal cord
syndrome with acute worsening by hemorrhage or
mass effect. Most patients present with progressive
or stepwise clinical deterioration which is thought
to be due to gliosis, microthrombosis, microcircula-
tory changes, and repeated minor bleedings into
the spinal cavernous angioma. Acute and severe
neurological symptoms can occur due to hemor-
rhage into the spinal cord [21]. Spinal cavernous
angiomas may be treated surgically when indicated
[2, 22, 23]. Most symptomatic or neurologically de-
clining patients with spinal cavernous angioma are
surgical candidates [21, 24].
Treatment
There are no prospective or randomized studies comparing different
treatment options in patients with ASCIS, acute spinal cord hemorrhage,
or spinal vascular malformations. Therefore, scientific evidence on
treatment of vascular diseases of the spinal cord is limited. A large
multicenter study would be needed to gain enough statistical power in
these rare diseases.
Treatment of acute spinal cord ischemia syndrome (ASCIS)
Treatment recommendations of ASCIS concerning acute stage and sec-
ondary prevention are derived from acute cerebral ischemia, atheroscle-
rotic vascular disease, and acute spinal cord injury. Besides acute
management, secondary prevention is of major importance. An underlying
pathology (eg, systemic vasculitis, aortic pathology, cardiogenic embolism,
hypovolemia, anemia) should be treated whenever possible [6, 10••,
11••] Class I).
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Pharmacological treatment
Acetylsalicylic acid
As for acute treatment of cerebral ischemia acetylsalicylic acid is used for
ASCIS in most centers [10••] (Class I).
Standard dosage We administer 250 mg up to 500 mg intravenously in the acute stage, fol-
lowed by 100 mg oral per day for secondary prevention. The AHA guidelines
recommend the following dosages: In the acute stage: 325 mg oral, for sec-
ondary prevention: 50 mg up to 325 mg oral [10••, 11••] (Class I).
Contraindications Hypersensitivity to salicylates and/or other anti-inflammatory drugs,
history of gastrointestinal hemorrhage, or bleeding diathesis, gastroin-
testinal ulcera, severe liver insufficiency, severe renal insufficiency, last
trimenon of pregnancy.
Main drug interaction Increased bleeding risk when administered with other platelet inhibitory or
anticoagulant drugs.
Main side effects Abdominal pain, gastrointestinal hemorrhage, or other bleeding, hypersen-
sitivity reactions.
Acetylsalicylic acid and dipyridamol or clopidogrel
Instead of acetylsalicylic acid, a combination therapy of acetylsalicylic
acid and dipyridamol may be administered. In case of occurrence of
ASCIS in patients already on treatment with acetylsalicylic acid, or in case
of hypersensitivity to acetylsalicylic acid, oral clopidogrel may be used. In
the acute stage we usually administer 75 mg, or a loading dose of
300 mg, followed by 75 mg (according to AHA guidelines) per day for
secondary prevention.
In the long term, daily administration of acetylsalicylic acid alone or
togetherwith dipyridamol, or clopidogrel alone reduce the risk of secondary
vascular events and death [10••, 11••] (Class I).
Thrombolytic therapy (eg, alteplase; tissue plasminogen
activator)
Thrombolytic therapy has been successfully used in few published
case reports of ASCIS [5, 25]. However, randomized controlled trials
on thrombolysis in patients with ASCIS are lacking. Therefore,
thrombolysis remains experimental. Before initiation of thromboly-
sis, the diagnosis has to be certain and contraindications have to be
excluded. This may lead to a delay beyond the established treatment
window for intravenous thrombolysis of 4.5 hours, derived from
evidence in patients with acute cerebral ischemia.
Standard dosage of alteplase as in
cerebral ischemia
0.9 mg/kg (maximum dose 90 mg), first 10 % administered as bolus within
1 minute and the remaining over 1 hour [26, 27] (Class I).
Contraindications First symptoms more than 4.5 hours ago, hypersensitivity to the substance,
acute intra- or extracranial bleeding, and/or bleeding less than 3 months ago,
vascular malformations, aortic dissection, traumatic brain injury less than
3 months ago, surgery, or biopsy of a parenchymatous organ, gastrointestinal
bleeding, pregnancy and birth less than 30 days ago, arterial tap in a non-
compressible location less than 7 days ago, infectious endocarditis,
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assumed septic embolus, hemorrhagic diathesis or coagulopathy, arterial
hypertension, that cannot be lowered (9185 mm Hg systolic and/or
9100 mm Hg diastolic), severe accompanying disease, INR 91.7, thrombo-
cytes G100 G/l, etc. [26, 27] (Class I).
Main drug interactions Increased bleeding risk when administered with anticoagulant or platelet
inhibitory drugs. Orolingual angioedema and anaphylaxis may occur, usu-
ally when receiving concomitant angiotensin-converting enzyme (ACE)
inhibitors.
Main side effects Bleeding.
Systemic corticosteroids
Treatment with systemic corticosteroids has not been studied in patients
with ASCIS apart from case reports. Furthermore, administration of
corticosteroids is not recommended in acute cerebral ischemia [10••, 25]
(Class I). Therefore, treatment with corticosteroids is not recommended
in patients with ASCIS.
Specific treatment with thoracic endovascular aortic repair (TEVAR)
ASCIS that occurs after aortic surgery is a feared complication. In repair involving
thoracic endovascular aortic repair (TEVAR) the risk of ASCIS appears to be lower
than for openprocedures.Moreover, protocols for the prevention and treatment of
delayed postinterventional ASCIS have been developed [4•, 28, 29] (Class III).
These protocols seem to be effective in reversing and limiting the neurological
deficits and consist of an immediate combination of blood pressure support by
volume and/or vasopressor agents and an immediate reduction of spinal cord
canal pressure with lumbar drains. These protocols have not yet been evaluated in
a controlled study in ASCIS and in ASCIS due to other causes than aortic inter-
ventions. The benefit in other causes is questionable especially because of the time
delay from symptom onset to clinical presentation.
Treatment of acute spinal cord hemorrhage
Pharmacological treatment
There are only limited pharmacological options to treat spinal cord hemor-
rhage. Vitamin K, fresh frozen plasma, and prothrombin complex may be
used for hemorrhages induced by vitamin K antagonists, protamin sulfate for
heparin-induced hemorrhages, platelet transfusions for thrombocytopenia,
specific clotting factor concentrates or, fresh frozen plasma for clotting factor
deficiencies as hemophilia A and hemophilia B (Christmas disease) [30].
Other specific pharmacological treatment is not proven.
Nonpharmacological treatment
The aim of immediate surgery in patients with acute spinal cord hemorrhage
is stopping of the bleeding, decompression of neural structures and removal
of the hematoma. Surgery may be indicated for hematomyelia [13]. In
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patients with subdural hemorrhage, surgery is often necessary as it is
mostly the case in patients with epidural hemorrhage [12, 31]. The
milder the preoperative symptoms and the quicker surgical decompres-
sion can be performed, the better are the chances for complete recovery
[12]. A report of few patients with spontaneous spinal epidural hemor-
rhages showed an improvement of symptoms even if surgery was per-
formed not earlier than 36 hours after symptom onset [32]. However,
there are some reports in patients with epidural hemorrhage that favor a
conservative approach in the following situations: Either in case of im-
proving symptoms between symptom onset and diagnosis or in case of a
longitudinally extending, less restricted compressive hematoma [31, 33].
Treatment of spinal subarachnoid hemorrhage and hematoma depends
on etiology and might be an urgent intervention for decompression.
Underlying spinal arteriovenous malformations should be treated as
listed below. Conservative treatment with bed rest is a treatment option
for patients with spinal subarachnoid hemorrhage and hematoma with
stable and minimal neurological impairment [34].
Acute symptomatic treatment of ASCIS and acute spinal cord hemorrhage
Within the first days up to weeks of hospitalization, patients with a spinal
cord lesion are at risk for several systemic as well as neurological complica-
tions. These complications may be life-threatening. Early intervention is
necessary. Intensive care unit admittance for strict monitoring of vital signs
and neurological status is necessary in patients with a cervical or a high
thoracic lesion [35•].
Cardiovascular complications
Cardiovascular complications are often caused by neurogenic shock,
which leads to arterial hypotension, usually accompanied by bradycardia.
Hemodynamic instability may be related to the underlying etiology.
Strict blood pressure control is necessary to maintain adequate perfusion.
A combination of volume resuscitation and the use of vasopressors with
chronotropic and inotropic properties (norepinephrine, dopamine) are
treatment options. Continuous blood pressure monitoring is recom-
mended. Bradycardia is frequently seen in high cervical (C1 up to C5)
lesions. External pacing or administration of atropine may be needed.
Autonomic dysreflexia, eg, episodic paroxysmal hypertension to very
high levels with headache, tachycardia or bradycardia, flushing, sweating
and anxiety/agitation may be seen in cervical, and upper thoracic cord
lesions, though autonomic dysreflexia was originally described after
traumatic spinal cord injury. The complication of autonomic dysreflexia
is dramatic and life-threatening. It is thought to arise from inappropriate
release of catecholamines from adrenal glands in response to visceral
stimuli. Therefore, treatment aims at relieving stimuli on bowel and
bladder decompression in order to control blood pressure. Arterial vas-
odilators and intravenous benzodiazepines can be given to control blood
pressure [36].
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Respiratory complications
Chest physiotherapy should be installed as soon as possible. Atten-
tion to the respiratory system should especially be given in patients
with higher cervical but also thoracic lesions. Respiratory complica-
tions as pneumonia, pulmonary embolism, pulmonary edema, and
respiratory failure may occur. Increased respiratory rate, declining
forced vital capacity, rising pCO2, or falling pO2 are signs of
impending respiratory failure, and indicate urgent intubation and
pressure support ventilation.
Venous thrombo- and pulmonary embolism
The risk of thromboembolic disease, including deep venous thrombosis
(DVT) and pulmonary embolism in patients with vascular diseases of the
spinal cord is increased, mainly due to immobilization and to decreased
muscle contraction because of paresis. Low-molecular-weight heparin
(LMWH) is considered the treatment of choice besides mechanical means
and mobilization. LMWH is recommended as soon as primary hemostasis is
achieved and the risk of bleeding or re-bleeding is low [35•, 37••, 38•].
Urinary catheterization
Prevention and treatment of urinary tract infections is important. On ad-
mission, urinary catheterization should be installed to avoid bladder dis-
tension. In the long term, intermittent straight catheterization to decompress
the urinary bladder is preferable, due to a higher risk of bladder infections
with an in-dwelling urinary catheter.
Pain control
Adequate pain management is important. In addition to nonsteroidal in-
flammatory and opioid agents, the use of pregabalin, gabapentin, or
duloxetin to treat neuropathic pain may be indicated. Antispasmodics may
also be helpful [35•].
Temperature control
An optimal ambient temperature should be maintained, as patients with spinal
cervical cord lesion might have difficulties controlling their body temperature,
secondary to an inability to sweat below the level of the lesion.
Gastrointestinal stress ulceration
Especially patients with cervical cord lesions are at high risk for stress ulcer-
ation and should receive prophylaxis with proton pump inhibitors.
Pressure sores
Pressure sores, especially on the buttocks and heels, can develop
quickly in immobilized patients. For prevention, patients have to be
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turned side to side (log-rolled) regularly, every 2 to 4 hours. Special
mattresses can also be used.
Functional recovery
Early mobilization is important for good lung and cardiovascular
function, and the prevention of pressure ulcers and venous stasis.
Physiotherapy and occupational therapy should be started as soon as
possible. If needed, psychological support and social workers might be
beneficial.
Long-Term symptomatic treatment of ASCIS and acute spinal cord hemorrhage
Often, patients after ASCIS and after acute spinal cord hemorrhage suffer
from residual deficits which are causing secondary complications including
bladder, bowel, and sexual dysfunction, spasticity, and chronic pain. These
conditions have to be managed [35•].
Treatment of spinal vascular malformations
Each spinal vascular malformation is a unique lesion that needs an in-
dividualized treatment algorithm. Due to few data, the natural history of
an asymptomatic incidental finding is difficult. It is generally accepted that
symptomatic vascular malformations should be treated whenever possible.
In case of an assumed high treatment risk, an observation of the spinal
dural AVM, AVF, or the spinal dural cavernous angiomas is warrantable in
individual cases. Spinal dural AVF should be treated without delay, since
short- and medium-term prognosis are poor and chances of favourable
outcome after treatment are good [16, 18] (Class III).
Treatment should only be performed in specialized centers with vascular
neurosurgeons, interventional neuroradiologists, and neurologists.
Pharmacological treatment
There are no drugs that have the capacity to affect or heal vascular malforma-
tions. Steroids may be helpful for a short period to improve the patient’s
symptoms by reducing vasogenic edema. However, steroids should only be
prescribed for a short period because of their adverse systemic short- and long-
term effects (eg, immunosuppression, hyperglycemia, gastric ulceration, and
psychosis) [30].
A successful occlusion of a spinal dural AVF leads to immediate hemody-
namic changes of the dilated intrathecal veins. Therefore, an additional hepa-
rinization for prevention of peri- and postinterventional thrombosis of the
dilated veins is recommended [39].
Interventional procedures
The possible interventional approach is endovascular embolization [40••].
Spinal AVM can be treated by embolizationwith liquid embolizationmaterial,
rarely particles or coils [15, 18] (Class IV). Spinal AVM are rather treated
endovascularly than surgically. The benefit of endovascular treatment of
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spinal dural AVF compared with surgical treatment is that it is less invasive,
preserving tissue and, therefore, function of the surrounding spinal cord.
However, there is a relevant percentage of spinal dural AVF that are tech-
nically not achievable endovascularly, even not in specialized centers. If
there is no complete occlusion of the venous side, then collaterals of the
neighbouring segmental arteries are to expect with consecutively missing
improvement or progression of symptoms and deficits. Therefore, after
endovascular treatment, regular clinical and imaging follow-ups are needed
[14–16, 18, 39, 41].
Surgery
Possible surgical treatment options are ligation, disconnection, or resection.
Spinal AVM, AVF, and spinal cavernous angiomas may be treated surgically.
Preoperative localization of the fistula is often recommended, however, surgical
treatment spinal dural of AVFmay be the first treatment choice. After opening of
the dura, the draining radiculomedullary vein has to be occluded. This leads to a
complete disconnection of the spinal dural AVF [17, 41]. In case of multiple sites
of fistula formation, surgery has the advantage of direct visibility of all feeding
vessels. Surgical disconnection of spinal dural AVF is a rather safe and straight-
forward surgical procedure at specialized centers with favorable long-term im-
provement of symptoms. Furthermore, surgery is the only option, if the arterial
feeding vessel is impossible to access endovascularly because of tortuous vascular
anatomy, or if the vessel supplies blood to healthy regions of the spinal cord.
Surgery is the treatment option of spinal cavernous angiomas [22]. The indi-
cation for surgery must carefully weight surgical risks against the natural history
of the disease. The risk for permanent neurological decline after surgery is esti-
mated to be 6 % to 12 % with most patients (44 % to 80 %) showing im-
provement after surgical resection [24]. Since current available data indicate
bleeding rates of 2.5% to4.5%per year,most centers treat – (eg, surgically resect
spinal cavernous angiomas) [21, 24]. There are few data that report about the
lack of rebleeding with a conservative approach [23]. Symptomatic and exo-
phytic spinal cavernous angiomas should be excised whereas deep intrinsic
spinal cavernous angiomas with only mild symptoms should be observed [21].
Combined interventional and surgical therapy
Current optimum treatment can only be reached by case discussion and an indi-
vidualized treatment plan that is established by an interdisciplinary team of spe-
cialized vascular neurosurgeons, interventional neuroradiologists, and
neurologists on a case by case basis in neurovascular centers.
Radiation therapy
Radiation therapy is still sometimes applied to spinal AVM and spinal
cavernous angiomas. In our opinion it may rarely be a treatment op-
tion in few spinal AVM, but is, especially in spinal cavernous angio-
mas, no longer an acceptable treatment option because of the high
radiation sensibility of the myelon.
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